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Conventional enteric coating requires the use of organic based polymers which are equally hazardous to 
the environment and operating personnel. Hot-melt coating avoids the use of solvents and is a safer and 
time-saving process. The present study was designed to assess the efficacy of hot-melt coating (HMC) 
as an enteric coating technique. Pellets prepared by extrusion spheronization were selected as the core 
formulation for a model of the gastric irritant drug diclofenac sodium (DFS) because of their innate 
advantages over single-unit formulations. Stearic acid (SA) and palmitic acid (PA) were evaluated as 
enteric hot-melt coating materials. HMC was carried out in a specially modified coating pan by applying 
SA and PA in molten state onto preheated pellets to achieve a coating level of 5-15 %w/w. Hot-melt 
coated pellets were evaluated for disintegration pH and in vitro dissolution in the pH range 1.2 to 6.8, 
along with basic micromeritics. SEM of coated pellets showed a uniform and smooth coating. These 
results indicated that HMC of both SA and PA exhibited very good enteric coating ability. The coated 
pellets showed negligible drug release in acidic pH. As the pellets were subsequently transferred to a 
higher pH level, a gradual increase in release of the drug from the pellets was observed with increasing 
pH of the dissolution media. The release was dependent upon coating extent, providing sustained enteric 
release as opposed to abrupt release with mixed release kinetics.
Uniterms: Pellets/coating/evaluation. Enteric coating/evaluation. Hot-melt coating/evaluation. 
Disintegration pH. Diclofenac sodium/pellets/coating. Palmitic acid/pellets/coating. Stearic acid/pellets/
coating.
O revestimento entérico convencional requer o uso de polímeros orgânicos os quais são igualmente 
danosos ao meio ambiente e ao pessoal que o executa. O revestimento por fusão a quente evita o uso de 
solventes e é processo mais seguro e que consome menos tempo. O presente estudo foi planejado para 
avaliar a eficácia do revestimento por fusão a quente (RFQ) como técnica de revestimento entérico. Os 
péletes preparados por esferonização por extrusão foram selecionados como formulação central para 
modelo de fármaco irritante gástrico, o diclofenaco sódico (DFS) em razão das vantagens inerentes 
sobre as formulações de única dose. O ácido esteárico (AE) e o ácido palmítico (AP) foram avaliados 
como materiais para o revestimento de fusão a quente. O RFQ foi realizado em recipiente especialmente 
modificado, aplicando AS e PA no estado fundido em péletes pré-aquecidos para atingir nível de 
revestimento de 5 a 15% p/P. Os péletes revestidos por fusão a quente for avaliados quanto ao pH de 
desintegração e à dissolução in vitro na faixa de pH de 1,2 a 6,8, juntamente com base micromerítica. 
O SEM dos péletes revestido mostrou revestimento uniforme e plano. Esses resultados indicaram que o 
RFQ tanto do AE quanto do AP apresentou capacidade de revestimento muito boa. Os péletes revestidos 
mostraram pouca liberação do fármaco em pH baixo. Como os péletes foram, subsequentemente, 
transferidos para pH mais altos, observou-se aumento gradual na liberação do fármaco dos péletes com 
o aumento do pH do meio de dissolução. A liberação foi dependente da extensão do revestimento, sendo 
a liberação entérica controlada, contrariamente à liberação abrupta com cinéticas mistas.
Unitermos: Péletes/avaliação. Pílulas/avaliaçãoentérica. Fusão a quente revestimento/avaliação. 
Desintegração do pH. Diclofenaco sódio/pílulas/revestimento. Palmídico ácido/pílulas/revestimento. 
Esteárico ácido/pílulas/revestimento.
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INTRODUCTION
Enteric-coated dosage forms are designed to resist 
the acidic environment of the stomach and disintegrate 
in the higher pH environment of the intestinal fluid. The 
main reasons for using an enteric coating are to protect 
the stomach wall from the harmful effect of the drug in 
a dosage form (Petroski, 1989) or to prevent degradation 
of the drug by gastric contents (Levine et al., 1990). An 
enteric coating protects the drug during transit through the 
acidic medium of the stomach. Upon entering the higher 
pH environment of the duodenum, the coating is dissolved, 
and the drug becomes available for absorption. Such a 
coating also provides protection for the gut mucosa when 
the drug is capable of producing gastric distress or nausea 
due to irritation. Enteric coating can also be used to deliver 
the active ingredients that are optimally absorbed from a 
particular region of the intestine, e.g. to the upper part of 
the small intestine, so as to enhance the bioavailability of 
the drug.
The materials used for enteric coating are either 
water resistant or pH sensitive. Water resistant materials 
are digested or emulsified by intestinal juices while pH-
sensitive materials slowly swell and burst when solvated. 
These materials can be applied to solid dosage forms (i.e. 
granules, pellets, or tablets) from aqueous latex or pseu-
dolatex, dispersions, aqueous solutions of alkali salts, or 
organic solvent solutions. Enteric-coated systems utilize 
polymeric coatings that are insoluble in the gastric media 
and therefore prevent or retard drug release in the stomach. 
Various types of ionizable polymers are commercially 
available. The most commonly used pH-sensitive enteric 
polymers today include cellulose acetate phthalate, cel-
lulose acetate trimellitate, hydroxypropyl methylcellulose 
phthalate, and methacrylic acid copolymers. These poly-
mers dissolve at various pH levels ranging between 4.8 
and 7.2 (Healey, 1989).
Enteric coating is generally applicable to four major 
types of drug, namely, those that are:
- Unstable in the gastric milieu. Examples include eryth-
romycin, penicillin V, pancreatin, and insulin.
- Irritants to the gastric mucosa and cause unpleasant side 
effects such as nausea and vomiting. Examples include 
aspirin and other NSAIDS (e.g. naproxen).
- Suitable candidates for delayed-release (‘‘time controlled 
release’’) dosage forms, which provide a lag time of be-
tween 3 and 4 h (Healey, 1989).
- Drugs with site-specific absorption in the intestine.
The limitations of enteric-coated dosage forms 
include the possibility of duodenal irritation from caustic 
drugs and an increase in inter-subject variability due to the 
presentation to the small intestine of a dosage form that 
needs to undergo disintegration and dissolution versus a 
disintegrated and partially dissolved drug substance.
A common problem associated with water resistant 
polymer is that, to provide an enteric effect, the film might 
be so thick that if the dosage form travels too fast through 
the gastrointestinal tract, solubilization in the intestinal 
fluid may never be achieved. With many aqueous enteric 
coating formulations the risk is of premature drug release 
(permeation) through the enteric coat into the stomach. 
This can be due to increased permeability of the aqueous 
film coating (Heinamaki et al., 1994) or to high water 
solubility of the drug (Bianchini et al., 1991). If the active 
ingredients are freely water soluble, they may dissolve 
in the spray mist during the coating process, resulting 
in active ingredients being included in the film. Organic 
solvent-based systems have some disadvantages with re-
spect to ecological, toxicological and manufacturing safety 
concerns. This coating has been employed for a number of 
drugs, including potassium chloride, ammonium chloride, 
aspirin, diethylstilbestrol, erythromycin, and divalproex.
A “hotmelt” is any material that undergoes a transi-
tion from a solid or semi-solid state at a lower temperature, 
to a liquid or semi-liquid state at a higher temperature 
(Lorenzi et al., 2001). Receiving much attention recently, 
hot-melt coating systems have become an immerging area 
in the pharmaceutical industry and concerted effort has 
been made to develop alternatives to organic and aqueous 
polymer systems (Achanta et. al., 1997). There are various 
hot-melt coating techniques, including melt coating, hot-
melt spray coating, solid dispersion hot-melt coating, and 
hot-melt direct blending coating, melt granulation, melt 
extrusion, melt dispersion and pastillation (Gokonda et 
al., 1994; Kim et al., 2003; Nadia et al., 2002). Develop-
ment of novel lipophilic excipients has provided impetus 
to research in the area of processing techniques involving 
molten states (Sinchaipanid et al., 2004). Hot-melt coat-
ings have various advantages over coatings with polymer 
solutions or dispersions. The coating material can be ap-
plied without organic solvents, at a high application rate. 
Therefore shorter processing time is required for hot-melt 
coating. These coatings can be applied onto solid dosage 
forms in the form of hot melts, hot emulsions or suspen-
sions (colloidal particles). In basic hot-melt coating, the 
coating material is applied onto the substrate surface in 
the hot-melt state.
The objective of this study was to evaluate effective-
ness of hot-melt coating technique as a method to obtain 
enteric coating. Multiple-unit dosage form pellets were 
selected because they are equally distributed throughout 
the gastrointestinal tract and the gastrointestinal transit 
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time of such systems are more reproducible and repeatable 
than those of single-unit tablets or capsules (Davis et al., 
1984; Hardy et al., 1985).
Diclofenac sodium (DFS) was selected as the model 
drug because it has a tendency for causing gastric irrita-
tion and even ulceration in some cases and is an ideal 
drug candidate for enteric coating. Stearic acid (SA) and 




Diclofenac sodium was received as a gift sample 
from Zim laboratories Ltd., Nagpur, India. Stearic acid 
and Palmitic acid were purchased from S.D. Fine Chemi-
cals, India. Microcrystalline cellulose (Avicel PH 101), 
Lactose monohydrate and Povidone (Kollidon 30) were 
generously gifted by FMC biopolymer (Mumbai, India), S. 
D. Fine Chemicals (Mumbai, India) and BASF India Ltd. 
(Mumbai, India), respectively. All other reagents were of 
analytical grade and used as received.
Methods
Preparation of pellets
The composition of various batches is given in 
Table I. Pellets of DFS with microcrystalline cellulose 
(MCC Avicel PH 101) – lactose monohydrate were pre-
pared by extrusion spheronization using Povidone (Kolli-
don 30) as a binder and water as the granulating fluid. A 
damp mass was prepared by mixing DFS, MCC, lactose 
and granulating this with binder solution. The damp mass 
was then extruded through a die-roller extruder (EXT-
65/10-2000, Umang Pharmatech, India). Extrudes were 
spheronized using a spheronizer (SPH-150/05, Umang 
Pharmatech, India) with a 1.2 mm cross hatch plate at 
900 rpm for 5 minutes. The pellets were dried at 60 °C 
for 2 hours in a hot air oven (SMC-120, Spectrum Pvt. 
Ltd., Mumbai).
Hot-melt coating of pellets
A modified coating spray gun was fabricated for 
the hot-melt coating. The gun consisted of three parts 
viz. spraying assembly, air handling system and coating 
chamber. The spraying system consisted of a spray gun 
with an air atomization nozzle attached to the feed input 
port. The nozzle was a pneumatic type two fluid nozzle 
with a needle valve for regulating flow rate of coating 
material. A feed input port provides coating material, 
maintained at a specific temperature with a mini immer-
sion heater, to the nozzle from a feed reservoir mounted 
on it. An air input port from an air handling system was 
also attached to this junction. The diameter of the feed 
output port was 1 mm and that of air output port was 2.5 
mm. The air handling system consisted of an air heat-
ing unit and air compressor. The air heating assembly 
comprised a 2.5-ft long steel pipe with an inner diameter 
of 1.5 inch. A 1000 watt heating coil insulated with bo-
rosilicate glass pipe placed between coil and metal pipe 
was inserted into the steel pipe. Current supply to the coil 
was provided through T joints at the ends of the metal 
pipe through a thermostat. The steel pipe was insulated 
with an insulating glass wool jacket. An air pressure com-
pressor (0.5 HP) with a 3.37 CFM displacement capacity 
was attached to the steel pipe to provide actuating air 
pressure. Compressed air was passed through the heating 
unit and fed into the nozzle through the air input port. 
The coating chamber was a pear-shaped stainless steel 
coating pan 4 inches in diameter with 4 tubular baffles 
and a maximum capacity of 0.5 liters. It was attached to 
the shaft of a single drive motor with a rotation speed of 
35 rpm and can be dismantled for cleaning. 
Two waxes were selected for the hot-melt coating 
(HMC), namely, SA and PA. The waxes were melted in 
separate containers. Pre-weighed drug-containing pellets 
were placed into the hot-melt coating pan and allowed 
to attain a temperature of about 50 °C. The molten wax 
was sprayed over tumbling pellets in small installments 
with constant rotation of the pan. After each addition, the 
pan was allowed to rotate for a further period of around 5 
minutes and then the next installment of wax was added. 
The coating level was determined by frequently taking 
weight readings of the coated pellets until the desired 
coating level was achieved.
TABLE I - Formulations of SA and PA coated pellets. All 
quantities indicated in %w/w basis. DFS- Diclofenac sodium, 
SA- Stearic acid, PA- Palmitic acid
Ingredients
Formulations
F1 F2 F3 F4 F5 F6
Pellet Composition
DFS 20 20 20 20 20 20
MCC 47 47 47 47 47 47
Lactose 30 30 30 30 30 30
PVP 3 3 3 3 3 3
Coating Composition
SA# 5 10 15 - - -
PA# - - - 5 10 15
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Evaluation of hot-melt coated pellets
The hot-melt coated sustained release pellets were 
evaluated for the following parameters.
· Size Distribution (Fekete et al., 1998):
The size distribution was determined using a sieve 
shaker and set of 4 ASTM sieves (# 10, #14, #20, and 
#30) for 5 minutes. The size distribution expresses the 
efficiency of the process to manufacture uniform-sized 
pellets. Mean pellet size was calculated according to the 
following equation.
· Crushing strength and friability of the pellets (Gandhi 
et al., 1990):
The crushing strength of hot-melt coated pellets 
was examined by a Veego digital dial type hardness tester 
(Veego Scientific, India).
For the friability study, a 1.0 g pre-weighed sample, 
collected on a sieve having 0.85 mm apertures with 25 
glass beads (3 mm in diameter) were placed in a Roche 
friabilator (Veego India Ltd.) and operated for 100 
revolutions at a speed of 25 rpm. The mass of pellets was 
collected again on a sieve with 0.85 mm apertures. The 
smaller particles were allowed to pass through the sieve 
and pellets reweighed. Friability was determined as the 
percentage loss of mass of the pellets post test.
· Determination of bulk and tapped density:
For measuring bulk density, 25 g of pellets of 14/20 
mesh fraction were poured gently through a glass funnel 
into a 100 ml calibrated measuring cylinder. The surface 
was carefully made smooth. The density was then calcu-
lated by dividing weight by volume.
The tapped density was also measured in a similar 
fashion as bulk density but the final volume was measured 
after the cylinder was tapped from the height of 3 inches 
until a constant volume was obtained. Compressibility in-
dex and Hausner ratio were determined from bulk density 
and tapped density values.
· Determination of drug content:
The drug content was determined by weighing 
crushed sample equivalent to 50.0 mg of Diclofenac 
sodium. The sample was diluted with 6.8 pH phosphate 
buffer and sonicated for 20 minutes (3.5L 100, PCi, Mum-
bai, India), centrifuged and filtered through 1µm finer 
porosity filter. A 5.0 mL volume of this solution was taken, 
the sample diluted suitably and absorbance measured at 
276.0 nm using a UV spectrometer (Shimadzu-UV-150-02 
Kyoto, Japan).
· Scanning electron microscopy:
The coated pellets were sputtered with gold for 5 
min using a sputter coater (Auto Fine Coater, JFC-1300, 
Jeol, Tokyo, Japan). The surface was examined by scan-
ning electron microscopy (SEM, Jeol JSM 5600 LV, Jeol, 
Tokyo, Japan) at 10 kV.
· Determination of disintegration pH of pellets (Marvola 
et al., 1999).
Release rate of the DFS from uncoated and coated 
pellets was studied as a function of gradual increase in 
pH of the dissolution medium (Marvola et al., 1989). The 
test was carried out on a USP XXIV type I dissolution test 
apparatus. Initially, the pellets were placed in a basket. A 
500 mL volume of 0.1 M HCl (pH 1.2) was taken as the 
dissolution medium and stirred at 50 rpm. After an initial 
period of 15 min, the pH was gradually increased every 
tenth minute by addition of 0.4 M disodium hydrogen 
phosphate. Drug concentrations prior to each addition of 
Disodium hydrogen phosphate were measured spectropho-
tometrically after alkalization by 1 N NaOH at 276 nm. 
Maximum dissolution rate of the model drug was consid-
ered indicative of the pH value at which pellet disintegra-
tion had occurred. This test provides some notion of the 
suitability of these materials as enteric coating materials.
Drug release study
In vitro drug release from hot-melt enteric coated 
pellets was assessed using dissolution a testing apparatus 
USP XXIV type I (Veego Scientific India, Ltd.) at 100 rpm 
in 900 mL of 0.1 N HCl for the first 2 hours followed by 
pH 6.8 Phosphate buffer. The percentage drug released 
from the pellets was determined using UV-spectroscopy 
with reference to a linear calibration curve at a wavelength 
of 276 nm. The dissolution data was computed in light 
of different kinetic equations (Costa et al., 2001) to help 
clarify the release mechanism of the drug from the hot-
melt enteric coated pellets.
RESULTS AND DISCUSSION
Evaluation of hot-melt enteric coated pellets
The results of the evaluation of pellets are sum-
marized in Table II. All the batches prepared by extrusion 
spheronization showed very good micromeritic proper-
ties. The application of the hot-melt coating of SA and PA 
resulted in further improvement of these properties.
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PA formed a comparatively smoother and elegant 
pellet coat than SA. The pellets had very good uniformity 
as desired and all formulations were within the size range 
of 800 to 1000 μ after hot-melt coating and exhibited a 
shape approaching that of a sphere. Values of angle of 
repose were approximately 18-25○ for all formulations. 
The surface was very smooth and particle size distribution 
was narrow. All these factors yielded very good flowabil-
ity. Friability was negligible, having a maximum value 
of 0.2%. This value can be attributed to the loosening of 
some wax from the coating due to attrition of the friability 
test. Pellet hardness, measured with a dial type hardness 
tester (Veego India Ltd.), was around 1.5 kg/cm2. Both 
these values indicated that the pellets had good mechani-
cal strength.
Scanning electron microscopy (SEM)
Figures 1-6 show microphotograph and scanning 
electron micrographs of hot-melt enteric coated pellets. 
Scanning electron microscopy was performed to study 
surface morphology. The scanning electron micrographs 
show a smooth surface and uniform coating. Pellets also 
exhibited a spherical shape.
Determination of disintegration pH
The disintegration pH was considered the pH at 
which coated pellets showed the highest amount of drug 
release at minimum fixed time. The material must be 
solubilized at alkaline pH to be considered suitable for 
enteric coating. Only results of 5% wax coated pellets 
were shown for this test as the time period for the test was 
very short and not adequate for release from pellets with 
higher percent coatings i.e. 10% and 15%. Due to lower 
extent of coating, an amount of the drug was also found to 
be released at acidic pH. This might have been due to coat-
ing erosion and not solubilization as the core pellets were 
intact even after completion of the test. The drug release 
gradually increased with greater pH levels as can be seen 
FIGURE 1 - Photograph of stearic acid coated pellets.
FIGURE 2 - Scanning electron micrograph of stearic acid coated 
pellets (30X). FIGURE 4 - Photograph of palmitic acid coated pellets.
FIGURE 3 - Scanning electron micrograph of stearic acid coated 
pellets (500X).
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in the graph. Contrary to previous studies (Marvola et al., 
1999) however, the drug release, although increased, was 
not abrupt but instead showed a slow and steady rise in 
release. This indicated that the PA and SA resist the gastric 
environment and will not release drug suddenly but gradu-
ally in the intestinal environment.
In vitro dissolution
The dissolution study was carried out to determine 
the resistance of the materials viz. SA and PA to the acidic 
environment of the stomach and their suitability as enteric 
coating materials. Ideally for enteric coating, there should be 
no release of drug in the acidic pH of the stomach, where this 
was determined in vitro by carrying out dissolution at 0.1 N 
HCl for the first two hours. Dissolution was subsequently 
continued in 6.8 phosphate buffer. The drug release data of 
the dissolution study is shown graphically in Figure 8. The 
gastric residence time of non-disintegrating pellets (diam-
eter 1–2 mm) under fasting conditions has been shown to 
be from 0.4 to 2 h, with a mean of 1.2 h (Hardy et al., 1985; 
Marvola et al., 1989). Intestinal transit times for different 
dosage forms, independently of diameter, are 2–4 h with a 
mean of 3 h (Clarke et al., 1993; Coupe et al., 1991). It can 
therefore be calculated that most of a pellet formulation 
should be at the end of the small intestine 4 h after drug 
administration (Marvola et al., 1999).
The graph indicates that both SA and PA exhibited 
very good enteric coating ability. Some drug was released 
FIGURE 6 - Scanning electron micrograph of stearic acid coated 
pellets (500X).
















F1 0.1 1.4 22.22 0.82 0.93 1.13 2.79 890
F2 0.0 1.5 20.86 0.82 0.93 1.13 11.58 899
F3 0.2 1.6 19.66 0.82 0.93 1.12 10.42 918
F4 0.1 1.4 21.97 0.82 0.92 1.12 10.48 864
F5 0.0 1.6 20.13 0.80 0.91 1.13 11.54 877
F6 0.1 1.6 18.98 0.87 0.89 1.03 11.33 894
Uncoated 0.2 1.3 25.33 0.78 0.88 1.13 10.23 840
FIGURE 7 - Disintegration pH of 5 %w/w enteric coated pellets 
as determined by drug release (mean ± SD, n = 3).
FIGURE 5 - Scanning electron micrograph of palmitic acid 
coated pellets (30X).
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in acidic pH at the lower coating level of 5%, whereas at a 
higher coating level there was practically zero drug release 
from the pellets. As the pellets were transferred to the high-
er pH level of 6.8, there was an abrupt increase in release 
of the drug from the pellets. This release was dependent 
upon coating extent. Significant differences were noted 
in the drug release pattern of the pellets containing 5 and 
15% wax coat. This suggests it is possible to retard drug 
release or extend lag time in relation to commencement of 
drug absorption by making the coat thicker at 15% rather 
than 5%. This is contrary to the findings with conventional 
enteric polymers (Aqoat AS-HF) as this polymer shows no 
significant effect of coatings above a 20% level (Marvola 
et al., 1999). This might be due to the inherent property 
of materials evaluated and their solubility mechanism. SA 
and PA first undergo saponification at higher pH and then 
become dissolved; it takes longer to dissolve the coat and 
increase drug release.
Release kinetics
The values for correlation coefficients according 
to the different kinetic equations are given in Table III. A 
release kinetics study according to goodness of fit shows 
that DFS followed the Peppas model (For Batch F1 to F4) 
for both waxes, indicating drug release by diffusion and 
erosion. The batch F5 and F6 showed release by zero order. 
The close proximity of correlation coefficients indicated 
that no single mechanism was completely dominant and 
confirmed that release was governed by more than one 
mechanism.
CONCLUSION
Both the studied hot-melt coating agents (PA and 
SA) were found to have good enteric coating ability. At 
a low wax coating level (5% w/w) negligible amounts of 
drug were released in the acidic environment after 2 hours. 
At and above a 10% coating, practically zero drug release 
was observed in acidic pH. A slower rate of drug release 
was observed with increased coating level.
The results of the present study showed that hot-melt 
coating materials can constitute an excellent alternative 
to conventional enteric polymers. The hot-melt coating 
technique can be an efficient, eco-friendly and economical 
tool for formulating enteric coated pellets.
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